Latest news

Filter by
Date
MEDIA RELEASE: Oct 11, 2017 08:33 AM

Blockchain tech: Garvan partners with E-Nome

Garvan has signed a memorandum of understanding with E-Nome Pty Ltd, an Australian technology startup driving the application of blockchain technology to the secure storage of health records. Together, Garvan and E-Nome ...

Oct 10, 2017 04:49 PM

The importance of returning research results to study partic...

Researchers from Garvan and the Australian Pancreatic Cancer Genome Initiative have explored the feasibility and value of returning the results of genomic research studies to study participants.

MEDIA RELEASE: Oct 06, 2017 05:00 AM

Biosensor mouse lights up health and disease

Garvan researchers have developed a biosensor mouse that gives a real-time readout of the rapidly changing ‘skeleton’ within cells. The researchers have watched cells respond dynamically to their surrounding environment ...

MEDIA RELEASE: Sep 22, 2017 06:42 AM

African prehistory: A long-awaited landscape revealed throug...

The first large-scale study of ancient human DNA from sub-Saharan Africa opens a long-awaited window into the identity of prehistoric populations in the region and how they moved around and replaced one another over the ...

Sep 18, 2017 06:00 PM

Now open: Zero Childhood Cancer program to deliver personali...

The Garvan Institute, with the Lions Clubs International Foundation and the Australian Lions Childhood Cancer Research Foundation, is proud to be a partner in the Zero Childhood Cancer national child cancer personalised ...

Sep 13, 2017 12:00 PM

Dubbo Osteoporosis Epidemiology Study

Take 5000 people, scrutinise for three decades and what do you get? A wholly new understanding of osteoporosis for starters, and the insights keep on coming.

Sep 11, 2017 08:51 AM

Vale Connie Johnson OAM

Vale Constance (Connie) Johnson OAM 1977 – 2017.

MEDIA RELEASE: Sep 10, 2017 07:30 AM

Type 1 diabetes: Releasing the 'insulin handbrake' could mak...

A Garvan-led research team has shown that a new therapeutic approach can enhance insulin secretion by the pancreas, and has the potential to improve islet cell transplants in individuals with type 1 diabetes

MEDIA RELEASE: Sep 07, 2017 10:48 PM

‘Partner in crime’ mutations work together to kickstart lymp...

Australian researchers have uncovered ‘extraordinary cooperation’ between two DNA mutations that are often found together in lymphomas and leukaemias. The findings help us understand how immune cells can ‘go rogue’, beha...

Sep 06, 2017 10:50 AM

Osteoporosis: major study identifies 150 new genetic sites t...

In the largest ever study of its kind, an international research team has identified over 150 new sites in the human genome that are linked to low bone mineral density and to an increased risk of fracture. The findings v...

Aug 31, 2017 01:20 PM

Professor Mark Febbraio: exercise is medicine

Garvan congratulates Professor Mark Febbraio, who has won the 2017 Australian Diabetes Society (ADS) Kellion Award. The award recognises an Australian researcher who has made an outstanding contribution to diabetes resea...

MEDIA RELEASE: Aug 23, 2017 06:00 AM

Ground-breaking trial brings personalised treatments to thos...

Garvan's Genomic Cancer Medicine Program, launched today by The Hon. Brad Hazzard, uses genomic medicine to match therapies, prevention and screening methods with rare cancer patients based on their genetic information.

Aug 16, 2017 07:09 AM

Rare Cancers Australia sets new agenda for change

Garvan is proud to support Rare Solutions: A Time to Act, a new report released by Rare Cancers Australia that sets out a roadmap for change in the treatment and care of patients with rare cancer in Australia.

MEDIA RELEASE: Aug 04, 2017 01:00 AM

Top-to-toe MRI screen picks up early-stage cancers while sti...

A major study shows that whole-body MRI screening can identify previously undetected primary tumours throughout the body in people with high genetic risk of cancer.

Jul 27, 2017 03:29 PM

Garvan reaches 15,000 genomes

Garvan has now sequenced more than 15,000 whole genomes, a major milestone for the Kinghorn Centre for Clinical Genomics (KCCG) and Garvan’s wholly owned subsidiary, Genome.One.

Jul 14, 2017 11:30 AM

Immunotherapy – changing the way we think about cancer treat...

Garvan scientists are looking beyond their specialty areas and taking an inter-disciplinary approach that is changing the way we think about the treatment of cancer.

MEDIA RELEASE: Jul 14, 2017 04:00 AM

We inherit more than DNA: the extra blueprint layer we can’t...

An international study has provided compelling evidence that we inherit more than a DNA blueprint from our mothers and fathers – we also inherit vital instructions on how to use that blueprint.

Jul 07, 2017 11:10 AM

Interleukin-2: releasing an immune system brake to attack tu...

Researchers from Garvan’s Immunology Division have been exploring ways to make interleukin-2 immunotherapy less toxic and more effective against cancer. In doing so, the team has uncovered surprising new information abou...

MEDIA RELEASE: Jun 30, 2017 05:00 AM

Promising new therapeutic approach rebuilds and strengthens ...

Garvan researchers demonstrate that a new therapeutic approach increases bone strength and resistance to fractures in multiple myeloma bone disease

MEDIA RELEASE: Jun 20, 2017 12:00 AM

Genome.One news: Australia’s first whole genome and health ...

Genome.One has today launched Australia's first clinical service that combines whole genome sequencing with a comprehensive health assessment to enable a more precise approach to managing health.

Jun 19, 2017 10:39 PM

Garvan joins the EMBL Australia family

Garvan is to become a member of the EMBL Australia Partner Laboratory Network. The news was announced at Garvan this month during the first EMBL Alumni event to be held in Australia.